Pharmacogenomics in Asia.
It is well known that genetic polymorphisms, such as SNPs, vary between races so that not only Western populations' pharmacogenetic/pharmacogenomic data but also data from Asians are viewed as vital to drug development and clinical practice. For this report, the current state of pharmacogenetic/pharmacogenomic-related activities in five Asian countries (China, Japan, the Republic of Korea, Singapore, and Taiwan) were researched and analyzed. The results show that there are multiple efforts underway in all of these countries, including the examination of guidelines, the implementation of projects to establish foundations for pharmacogenetics/pharmacogenomics, and several clinical trials, that have hardly been recognized up to now.
Tamaoki
Mieko
M
Product Evaluation Department, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan. tamaoki@yamanouchi.co.jp
Gushima
Hiroshi
H
Tsutani
Kiichiro
K
D001208:Asia; D001675:Bioethics; D004345:Drug Industry; D010597:Pharmacogenetics / Q000639:trends*; D012109:Research Support as Topic